Diagnosis and management of pediatric myocarditis

Pediatric Drugs

Volumn 4, Issue 3, 2002, Pages 171-181

  Bohn, D ^a   Benson, L ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIVIRUS AGENT; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; IMMUNOGLOBULIN; INOTROPIC AGENT; NITROPRUSSIDE SODIUM; PREDNISONE; VASODILATOR AGENT;

ADOLESCENT; ALGORITHM; ANAMNESIS; BIOPSY; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC ERROR; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MYOCARDITIS; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0036216739     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204030-00004     Document Type: Review

References (111)

1. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies
2. Myocarditis
3. Molecular aspects of myocarditis
4. Tracheal aspirate as a substrate for polymerase chain reaction detection of viral genome in childhood pneumonia and myocarditis
5. Viral myocarditis: Balance between viral infection and immune response
6. Acute myocarditis: Rapid diagnosis by PCR in children
7. Viral infection of the myocardium in endocardial fibroelastosis: Molecular evidence for the role of mumps virus as an etiologic agent
8. Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction
9. Viral myocarditis: Identification of five differentially expressed genes in coxsackievirus B3-infected mouse heart
10. A clinical trial of immunosuppressive therapy for myocarditis
11. Cardiomyopathy and myocarditis in children with ventricular ectopic rhythm
12. Occurrence of myocarditis in sudden death in children
13. The spectrum of presentation at autopsy of myocarditis in infancy and childhood
14. Sudden natural death in later childhood and adolescence
15. Sudden death in children and young adults
16. Immunosuppressive therapy in the management of acute myocarditis in children: A clinical trial
17. Gamma-globulin treatment of acute myocarditis in the pediatric population
18. Clinical outcomes of acute myocarditis in childhood
19. Familial dilated cardiomyopathy: Evidence for genetic and phenotypic heterogeneity
20. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy
21. Infantile dilated cardiomyopathy: Relation of outcome to left ventricular mechanics, hemodynamics, and histology at the time of presentation
22. Late recovery of ventricular function in children with idiopathic dilated cardiomyopathy
23. Clinical course of idiopathic dilated cardiomyopathy in children
24. Myocarditis: A histopathologic definition and classification
25. Persistence of viral genome into late stages of murine myocarditis detected by polymerase chain reaction
26. Cardiac persistence of cardioviral RNA detected by polymerase chain reaction in a murine model of dilated cardiomyopathy
27. The natural history of encephalomyocarditis virus-induced myositis and myocarditis in mice. Viral persistence demonstrated by in situ hybridization
28. Effects of immunosuppressive therapy in biopsy-proved myocarditis and borderline myocarditis on left ventricular function
29. Detection of coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy
30. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: An approach to the diagnosis of viral heart disease
31. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy
32. Differential effects of myocarditic variants of coxsackievirus B3 in inbred mice: A pathologic characterization of heart tissue damage
33. In situ immune autoradiographic identification of cells in heart tissues of mice with coxsackievirus B3-induced myocarditis
34. Phenotypic analysis of infiltrating cells in human myocarditis: An immunohistochemical study in paraffin-embedded tissue
35. Increased circulating cytokines in patients with myocarditis and cardiomyopathy
36. Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus
37. Tumour necrosis factor and inducible nitric oxide synthatase in dilated cardiomyopathy
38. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness
39. Negative inotropic effects of cytokines on the heart mediated by nitric oxide
40. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia
41. Nitric oxide and septic shock
42. Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis: A possible mechanism through inhibition of nitric oxide production
43. Enhanced expression of superoxide dismutase messenger RNA in viral myocarditis: An SH-dependent reduction of its expression and myocardial injury
44. Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus
45. Effect of delayed captopril therapy on left ventricular mass and myonecrosis during acute coxsackie virus murine myocarditis
46. Beneficial effects of captopril in acute coxsackievirus B3 murine myocarditis
47. Captopril suppresses interstitial fibrin deposition in coxsackievirus B3 myocarditis
48. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis
49. Beta-blocker treatment of dilated cardiomyopathy: Beneficial effect of carteolol in mice
50. A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis
51. Myocarditis misdiagnosed as sudden infant death syndrome (SIDS)
52. Lymphocytic myocarditis presenting as unexplained ventricular arrhythmias: Diagnosis with endomyocardial biopsy and response to immunosuppression
53. Corticosteroid therapy for ventricular tachycardia in children with silent lymphocytic myocarditis
54. Role of right ventricular endomyocardial biopsy in infants and children with suspected or possible myocarditis
55. Stokes-Adams attacks due to acute nonspecific myocarditis
56. Differentiating anomalous left main coronary artery originating from the pulmonary artery in infants from myocarditis and dilated cardiomyopathy by electrocardiogram
57. Favorable effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis
58. Viral myocarditis: Diagnosis and management
59. Cardiac troponin T in patients with clinically suspected myocarditis
60. Interobserver variability in the pathologic interpretation of endomyocardial biopsy results
61. Do endomyocardial biopsies represent the morphology of the rest of the myocardium?
62. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: Implications for role of sampling error
63. Risk of endomyocardial biopsy in immunosuppressed patients after cardiac transplantation
64. Complications of endomyocardial biopsy in children
65. Morphological considerations of peri- and myocarditis
66. Induction of major histocompatibility complex antigens within the myocardium of patients with active myocarditis: A nonhistologic marker of myocarditis
67. Classification of cardiomyopathies according to the WHO/ISFC Task Force: More questions than answer?
68. Active myocarditis in the spectrum of acute dilated cardiomyopathies: Clinical features, histologic correlates, and clinical outcome
69. Myocarditis in children with dilated cardiomyopathy: Incidence and outcome after dual therapy immunosuppression
70. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy
71. Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
72. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats
73. Calcium channel blocker-induced protection against cardiovascular damage
74. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: A preliminary study
75. Effects of intravenous milrinone on left ventricular function in ischemic and idiopathic dilated cardiomyopathy
76. Effect of oral milrinone on mortality in severe chronic heart failure
77. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy
78. Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor down regulation
79. Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy
80. More favourable haemodynamic effects from metoprolol than from captopril in patients with dilated cardiomyopathy
81. New therapeutic strategies in chronic heart failure: Challenge of long-term beta-blockade
82. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
83. Beta blockers for CHF: Adrenergic blockade dramatically reduces morbidity and mortality
84. Clinical trials of beta-blockers in heart failure: A class review
85. Cardiovascular effects of mechanical ventilation
86. Cardiac output response to continuous positive airway pressure in congestive heart failure
87. Effect of continuous positive airway pressure on intrathoracic and left ventricular transmural pressures in patients with congestive heart failure
88. Inflammatory cardiomyopathy (myocarditis): Which patients should be treated with anti-inflammatory therapy?
89. Effects of prednisolone on acute viral myocarditis in mice
90. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy
91. Immunosuppressive therapy in experimental and clinical myocarditis
92. Lack of objective improvement in ventricular systolic function in patients with myocarditis treated with azathioprine and prednisone
93. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy
94. Intervention in myocarditis and acute cardiomyopathy with immune globulin: Results from the randomized placebo controlled IMAC trial
95. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: Two-year follow-up results
96. Dilated cardiomyopathy caused by acute myocarditis in pediatric patients: Evolution of myocardial damage in a group of potential heart transplant candidates
97. The ineffectiveness of immunosuppressive therapy in lymphocytic myocarditis: An overview
98. Mechanical circulatory support in children with cardiac disease
99. Mechanical circulatory support for pediatric patients with acute myocarditis
100. Transient normalization of systolic and diastolic function after support with a left ventricular assist device in a patient with dilated cardiomyopathy
101. Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading
102. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy
103. Clinical experience with the MEDOS HIA-VAD system in infants and children: A preliminary report
104. Long-term outcome of patients with biopsy-proved myocarditis: Comparison with idiopathic dilated cardiomyopathy
105. The registry of the extracorporeal life support organization
106. Balloon atrial septostomy for left ventricular decompression in patients receiving extracorporeal membrane oxygenation for myocardial failure
107. Transseptal decompression of the left heart during ECMO for severe myocarditis
108. Extracorporeal life support for cardiac assist in pediatric patients: Review of ELSO registry data
109. Extracorporeal membrane oxygenation in the management of cardiac failure secondary to myocarditis
110. Circulatory support with paracorporeal pneumatic ventricular assist device (VAD) in infants and children
111. Children may survive severe myocarditis with prolonged use of biventricular assist devices